Trial Profile
A Multicenter, Open Label, Randomized Phase II Trial of Presurgical Treatment With Single-Agent Trastuzumab (H) or Lapatinib (Ty) or the Combination of Trastuzumab and Lapatinib (H+Ty), Followed by Six Cycles of Docetaxel (T) and Carboplatin) With Trastuzumab (TCH) or Lapatinib (TCTy) or the Combination of Trastuzumab and Lapatinib (TCHTy) in Patients With HER2/Neu-Amplified Operable Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Docetaxel (Primary) ; Lapatinib (Primary) ; Trastuzumab (Primary)
- Indications Adenocarcinoma; Early breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- 29 Oct 2020 Results published in the Clinical Cancer Research
- 14 Dec 2019 Analysis of microarray expression data from the TRIO-US B07 trial, results presented at the 42nd Annual San Antonio Breast Cancer Symposium
- 14 Dec 2019 Results, assessing the predictive biomarkesrs to predict the response to neo-adjuvant therapy (HER2 targeted) using digital spatial profiler, presented at the 42nd Annual San Antonio Breast Cancer Symposium